Progenics Pharmaceuticals Inc. (PGNX)

5.85
0.05 0.85
NASDAQ : Health Technology
Prev Close 5.90
Open 5.89
Day Low/High 5.73 / 5.92
52 Wk Low/High 3.42 / 6.31
Volume 419.96K
Avg Volume 1.31M
Exchange NASDAQ
Shares Outstanding 86.42M
Market Cap 498.65M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Progenics Pharmaceuticals Announces Delivery Of Consents And Revocations To Independent Inspector Of Elections

Progenics Pharmaceuticals Announces Delivery Of Consents And Revocations To Independent Inspector Of Elections

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical Therapeutics AZEDRA Commercial Dosing Progresses in U.

Progenics Reminds Shareholders That November 17 Is The True Deadline For Velan's Consent Solicitation

Progenics Reminds Shareholders That November 17 Is The True Deadline For Velan's Consent Solicitation

Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus Transaction in Order to Make a Fully Informed Final...

Progenics Urges Shareholders To Reject The Risk And Uncertainty That Would Be Caused By Giving Velan's Nominees Control Of The Board

Progenics Urges Shareholders To Reject The Risk And Uncertainty That Would Be Caused By Giving Velan's Nominees Control Of The Board

November 17 is the Only Deadline for Velan's Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 NEW YORK, Nov.

Progenics Reminds Shareholders That November 17 Is The Only Deadline For Velan's Consent Solicitation

Progenics Reminds Shareholders That November 17 Is The Only Deadline For Velan's Consent Solicitation

Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents Demanded by Velan Urges Shareholders to Review the S-4...

Progenics Strongly Agrees With ISS Recommendation That Velan Group SHOULD NOT Get Majority Control Of The Board Of Directors

Progenics Strongly Agrees With ISS Recommendation That Velan Group SHOULD NOT Get Majority Control Of The Board Of Directors

ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by Revoking Consent to ALL of Velan's...

Independent Director Candidates Nominated By Velan Issue Letter To Progenics Shareholders

Independent Director Candidates Nominated By Velan Issue Letter To Progenics Shareholders

Today, Dr. Gérard Ber released an open letter to stockholders of Progenics Pharmaceuticals, Inc.

PGNX Makes Notable Cross Below Critical Moving Average

PGNX Makes Notable Cross Below Critical Moving Average

In trading on Wednesday, shares of Progenics Pharmaceuticals, Inc. crossed below their 200 day moving average of $4.82, changing hands as low as $4.79 per share.

Velan Responds To Misleading Communications From Progenics

Velan Responds To Misleading Communications From Progenics

Velan Capital, L.P.

Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

Flags Velan's Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan's Questionable Securities Trading, Governance and Ethical Practices Asks Velan's Nominees if They Want to Be Associated with These...

Velan Sends Letter To Progenics Stockholders

Velan Sends Letter To Progenics Stockholders

Velan Capital, L.P.

Progenics Sends Letter To Shareholders

Progenics Sends Letter To Shareholders

Calls Out Velan's Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics' WHITE Consent Revocation Card NEW YORK, Oct.

Progenics Sends Letter To Shareholders

Progenics Sends Letter To Shareholders

Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and...

Lifshitz & Miller LLP Announces Investigation Of Arotech Corporation, Dova Pharmaceuticals, Inc., Highlands Bankshares, Inc., Progenics Pharmaceuticals, Inc., Proteon Therapeutics, Inc., Roan Resources, Inc., SemGroup Corporation And The Stars Group Inc.

Lifshitz & Miller LLP Announces Investigation Of Arotech Corporation, Dova Pharmaceuticals, Inc., Highlands Bankshares, Inc., Progenics Pharmaceuticals, Inc., Proteon Therapeutics, Inc., Roan Resources, Inc., SemGroup Corporation And The Stars Group Inc.

NEW YORK, Oct. 8, 2019 /PRNewswire/ -- Arotech Corporation (ARTX) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of Arotech to Greenbriar Equity Group, L.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 4, 2019 /PRNewswire/ --  WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc.

Possible M&A Surrounds These 3 Stocks

Possible M&A Surrounds These 3 Stocks

M&A activity has generally slowed.

INVESTOR ALERT: Monteverde & Associates PC Announces An Investigation Of The Following Merger

INVESTOR ALERT: Monteverde & Associates PC Announces An Investigation Of The Following Merger

NEW YORK, Oct. 3, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: Chardan Heathcare Acquisition...

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Progenics Pharmaceuticals, Inc. Has Obtained A Fair Price In Its Sale To Lantheus Holdings, Inc.

Shareholder Alert: Ademi & O'Reilly, LLP Investigates Whether Progenics Pharmaceuticals, Inc. Has Obtained A Fair Price In Its Sale To Lantheus Holdings, Inc.

MILWAUKEE, Oct. 3, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Progenics to Lantheus.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Progenics Pharmaceuticals, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc.

Velan Comments On Announced Sale Of Progenics To Lantheus

Velan Comments On Announced Sale Of Progenics To Lantheus

Velan Capital, L.P.

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus and Progenics Sink After Striking All-Stock Deal

Lantheus will acquire oncology medicine developer Progenics Pharmaceuticals in an all-stock deal.

Lantheus To Acquire Progenics To Form A Leading Precision Diagnostics Imaging And Therapeutics Company

Lantheus To Acquire Progenics To Form A Leading Precision Diagnostics Imaging And Therapeutics Company

Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc.

First Week Of May 2020 Options Trading For Progenics Pharmaceuticals (PGNX)

First Week Of May 2020 Options Trading For Progenics Pharmaceuticals (PGNX)

Investors in Progenics Pharmaceuticals, Inc. saw new options become available this week, for the May 2020 expiration.

TheStreet Quant Rating: D (Sell)